AB Science Completes EUR 1.8 Million Private Placement
Biopharmaceutical company AB Science announced on May 20, 2025, the successful completion of a capital increase totaling EUR 1.8 million. The funds were raised through a private placement subscribed by a limited number of investors.
PARIS – AB Science announced on May 20, 2025, that it has successfully closed a capital increase securing EUR 1.8 million in gross proceeds. The financing round was conducted as a private placement, with subscriptions coming from a limited group of investors.
The capital raised is intended to support the company's ongoing clinical development programs. AB Science focuses on the development of drug candidates for diseases with high unmet medical needs, including rare diseases and neurological disorders.
The company's research pipeline includes compounds such as masitinib, targeting neurodegenerative and inflammatory diseases, and AB8939 for oncology. The newly acquired funds are expected to contribute to advancing these drug candidates through clinical trials and toward potential regulatory submissions.
AB Science continues its research and development efforts aimed at bringing novel therapeutic options to patients. The company regularly updates stakeholders on its progress.